Trustmark National Bank Trust Department Trims Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Trustmark National Bank Trust Department lessened its position in shares of Amgen Inc. (NASDAQ:AMGN) by 14.6% during the 3rd quarter, Holdings Channel reports. The firm owned 25,944 shares of the medical research company’s stock after selling 4,449 shares during the quarter. Trustmark National Bank Trust Department’s holdings in Amgen were worth $8,359,000 as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of the company. Capital Performance Advisors LLP purchased a new position in shares of Amgen during the third quarter worth $25,000. Strategic Financial Concepts LLC acquired a new stake in Amgen during the 2nd quarter worth about $26,000. Hershey Financial Advisers LLC purchased a new position in shares of Amgen during the 2nd quarter valued at about $30,000. nVerses Capital LLC acquired a new position in shares of Amgen in the 2nd quarter valued at about $31,000. Finally, Bbjs Financial Advisors LLC purchased a new stake in shares of Amgen in the second quarter worth about $33,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Oppenheimer reissued an “outperform” rating and issued a $380.00 price target on shares of Amgen in a report on Wednesday, August 7th. Bank of America lifted their price target on Amgen from $325.00 to $330.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Citigroup started coverage on Amgen in a research report on Thursday, November 14th. They set a “neutral” rating and a $335.00 price target on the stock. Dbs Bank upgraded Amgen to a “strong-buy” rating in a research report on Monday, September 16th. Finally, Wolfe Research initiated coverage on shares of Amgen in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Amgen currently has a consensus rating of “Moderate Buy” and an average price target of $333.57.

Amgen Stock Up 2.8 %

Shares of AMGN opened at $287.87 on Thursday. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The firm has a market cap of $154.74 billion, a P/E ratio of 36.86, a price-to-earnings-growth ratio of 2.53 and a beta of 0.60. The company’s 50-day moving average price is $318.08 and its 200 day moving average price is $318.22. Amgen Inc. has a 12-month low of $260.52 and a 12-month high of $346.85.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. During the same quarter last year, the company posted $4.96 EPS. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. On average, sell-side analysts forecast that Amgen Inc. will post 19.51 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a dividend of $2.25 per share. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a yield of 3.13%. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.